Evidence map›Paper›PMID 35127675›Full record

ReviewFrontiers in bioengineering and biotechnology2021

Strategies for Heterologous Expression, Synthesis, and Purification of Animal Venom Toxins.

Esperanza Rivera-de-Torre, Charlotte Rimbault, Timothy P Jenkins, Christoffer V Sørensen, Anna Damsbo, Natalie J Saez, Yoan Duhoo, Celeste Menuet Hackney, Lars Ellgaard, Andreas H Laustsen

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in bioengineering and biotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
8.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 46 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Structural similarities reveal an expansive conotoxin family with a two-finger toxin fold.Protein science : a publication of the Protein Society · 2025
    Article
  9. Article
  10. Review
  11. Malacologia · 2025
    Article
  12. Review
  13. Prospects and challenges of recombinant spider venom enzymes: insights fromFrontiers in bioengineering and biotechnology · 2025
    Article
  14. Cnidarian toxins: omics approaches and recombinant proteins.The journal of venomous animals and toxins including tropical diseases · 2025
    Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Esperanza Rivera-de-TorreDepartment of Biotechnology and Biomedicine, Technical University of Denmark, Kongens Lyngby, Denmark.
Charlotte RimbaultDepartment of Biotechnology and Biomedicine, Technical University of Denmark, Kongens Lyngby, Denmark.
Timothy P JenkinsDepartment of Biotechnology and Biomedicine, Technical University of Denmark, Kongens Lyngby, Denmark.
Christoffer V SørensenDepartment of Biotechnology and Biomedicine, Technical University of Denmark, Kongens Lyngby, Denmark.
Anna DamsboDepartment of Biotechnology and Biomedicine, Technical University of Denmark, Kongens Lyngby, Denmark.
Natalie J SaezInstitute for Molecular Bioscience, The University of Queensland, St Lucia, QLD, Australia.
Yoan DuhooInstitute for Molecular Bioscience, The University of Queensland, St Lucia, QLD, Australia.
Celeste Menuet HackneyDepartment of Biology, Linderstrøm-Lang Centre for Protein Science, University of Copenhagen, Copenhagen, Denmark.
Lars EllgaardDepartment of Biology, Linderstrøm-Lang Centre for Protein Science, University of Copenhagen, Copenhagen, Denmark.
Andreas H LaustsenDepartment of Biotechnology and Biomedicine, Technical University of Denmark, Kongens Lyngby, Denmark.
Technical University of Denmark · DKUniversity of Copenhagen · DKUniversity of Queensland · AU

Funding

European Research Council 850974
6 · The paper itself

Abstract

Animal venoms are complex mixtures containing peptides and proteins known as toxins, which are responsible for the deleterious effect of envenomations. Across the animal Kingdom, toxin diversity is enormous, and the ability to understand the biochemical mechanisms governing toxicity is not only relevant for the development of better envenomation therapies, but also for exploiting toxin bioactivities for therapeutic or biotechnological purposes. Most of toxinology research has relied on obtaining the toxins from crude venoms; however, some toxins are difficult to obtain because the venomous animal is endangered, does not thrive in captivity, produces only a small amount of venom, is difficult to milk, or only produces low amounts of the toxin of interest. Heterologous expression of toxins enables the production of sufficient amounts to unlock the biotechnological potential of these bioactive proteins. Moreover, heterologous expression ensures homogeneity, avoids cross-contamination with other venom components, and circumvents the use of crude venom. Heterologous expression is also not only restricted to natural toxins, but allows for the design of toxins with special properties or can take advantage of the increasing amount of transcriptomics and genomics data, enabling the expression of dormant toxin genes. The main challenge when producing toxins is obtaining properly folded proteins with a correct disulfide pattern that ensures the activity of the toxin of interest. This review presents the strategies that can be used to express toxins in bacteria, yeast, insect cells, or mammalian cells, as well as synthetic approaches that do not involve cells, such as cell-free biosynthesis and peptide synthesis. This is accompanied by an overview of the main advantages and drawbacks of these different systems for producing toxins, as well as a discussion of the biosafety considerations that need to be made when working with highly bioactive proteins.

Indexed as

animal toxinsbioinsecticideheterologous expressionneurotoxinrecombinant protein expressionrecombinant toxinstoxin-inspired drugvenom

Identifiers

PMID35127675
PMCPMC8811309
OpenAlexW4206581495

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.